[1]
|
赵毅, 邓鑫. 乳腺癌分子分型与治疗策略[J]. 中国实用外科杂志, 2015, 35(7): 704-708.
|
[2]
|
李惠平. 不同分子类型乳腺癌的治疗策略和治疗后管理[J]. 癌症进展, 2016, 14(12): 1166-1166.
|
[3]
|
Fan, L., Strasser-Weippl, K., Li, J.J., et al. (2014) Breast Cancer in China. The Lancet Oncology, 15, e279-e289.
https://doi.org/10.1016/S1470-2045(13)70567-9
|
[4]
|
李明卉, 夏添松, 王水. 乳腺癌常用化疗药物的作用机制及血液学不良反应的研究进展[J]. 中华乳腺病杂志(电子版), 2017, 11(3): 186-190.
|
[5]
|
Van, H.S., Sparidans, R.W., Wagenaar, E., et al. (2017) Breast Cancer Resistance Protein (BCRP/ABCG2) and P-Glycoprotein (P-gp/ABCB1) Transport Afatinib and Restrict Its Oral Availability and Brain Accumulation. Pharmacological Research, 120, 43-50. https://doi.org/10.1016/j.phrs.2017.01.035
|
[6]
|
沈晓玲, 杨志宏. 多药耐药相关ABC转运蛋白信号转导通路研究进展[J]. 中国药理学与毒理学杂志, 2018, 32(10): 72-82.
|
[7]
|
Liu, T., Guo, J.C. and Zhang, X.X. (2019) MiR-202-5p/PTEN Mediates Doxorubicin-Resistance of Breast Cancer Cells via PI3K/Akt Signaling Pathway. Cancer Biology & Therapy, 20, 1-10.
https://doi.org/10.1080/15384047.2019.1591674
|
[8]
|
Liu, S.W., Chen, S., Yuan, W.G., et al. (2017) PD-1/PD-L1 Interaction Up-Regulates MDR1/P-gp Expression in Breast Cancer Cells via PI3K/AKT and MAPK/ERK Pathways. Oncotarget, 8, 99901-99912.
https://doi.org/10.18632/oncotarget.21914
|
[9]
|
Ong, C., Daemen, A., Oeh, J., et al. (2016) Breast Cancer Cell Lines with Acquired Resistance to Selective ERα Degraders (SERDs) Are Dependent on PI3K Signaling. Cancer Research, 76, 1803-1803.
|
[10]
|
Huemer, F., Bartsch, R. and Gnant, M. (2014) The PI3K/AKT/MTOR Signaling Pathway: The Role of PI3K and AKT Inhibitors in Breast Cancer. Current Breast Cancer Reports, 6, 59-70. https://doi.org/10.1007/s12609-014-0139-y
|
[11]
|
Arthur, J.S. and Ley, S.C. (2013) Mitogen-Activated Protein Kinases in Innate Immunity. Nature Reviews Immunology, 13, 679-692. https://doi.org/10.1038/nri3495
|
[12]
|
Kim, E.J. and Juhnn, Y.S. (2015) Cyclic AMP Signaling Reduces Sirtuin 6 Expression in Non-Small Cell Lung Cancer Cells by Promoting Ubiquitin-Proteasomal Degradation via Inhibition of the Raf-MEK-ERK (Raf/Mitogen-Activated Extracellular Signal-Regulated Kinase/Extracellular Signal-Regulated Kinase) Pathway. The Journal of Biological Chemistry, 290, 9604-9613. https://doi.org/10.1074/jbc.M114.633198
|
[13]
|
Wang, P.P., Luan, J.J., Xu, W.K., et al. (2017) Astragaloside IV Downregulates the Expression of MDR1 in Bel 7402/FU Human Hepatic Cancer Cells by Inhibiting the JNK/c-Jun/AP-1 Signaling Pathway. Molecular Medicine Reports, 16, 2761-2766. https://doi.org/10.3892/mmr.2017.6924
|
[14]
|
龙玲, 周琦, 张笠. p38MAPK 信号传导通路与卵巢癌关系研究进展[J]. 国际妇产科学杂志, 2017, 44(5): 494-498.
|
[15]
|
Zhou, Z., Qiao, J.X., Shetty, A., et al. (2014) Regulation of Estrogen Receptor Signaling in Breast Carcinogenesis and Breast Cancer Therapy. Cellular & Molecular Life Sciences, 71, 1549-1549.
https://doi.org/10.1007/s00018-013-1376-3
|
[16]
|
杜璟, 张晓丽, 蒋丽娜. 雌、孕激素受体和表皮生长因子受体在乳腺癌中的表达及其临床意义[J]. 中国老年学杂志, 2014, 34(19): 5405-5407.
|
[17]
|
逄晓玲, 王一丁, 朱杰, 等. 乳腺癌ER相关内分泌耐药机制的研究进展[J]. 转化医学电子杂志, 2017, 4(9): 62-65.
|
[18]
|
余沈桐, 韦伊芳, 马勇政, 等. 乳腺癌内分泌治疗耐药相关机制的研究进展[J]. 现代肿瘤医学, 2014, 22(9): 2240-2244.
|
[19]
|
Heckler, M.M., Thakor, H., Schafer, C.C., et al. (2014) ERK/MAPK Regulates ERRγ Expression, Transcriptional Activity and Receptor-Mediated Tamoxifen Resistance in ER+ Breast Cancer. FEBS Journal, 281, 2431-2442.
https://doi.org/10.1111/febs.12797
|
[20]
|
Shi, J.F., Yang, N., Ding, H.J., et al. (2014) ERα Directly Activated the MDR1 Transcription to Increase Paclitaxel-Resistance of ERα-Positive Breast Cancer Cells in Vitro and in Vivo. The International Journal of Biochemistry & Cell Biology, 53, 35-45. https://doi.org/10.1016/j.biocel.2014.04.016
|
[21]
|
Kazuyoshi, M., Satomi, T., Junko, M., et al. (2010) Estrogen-Mediated Post Transcriptional Down-Regulation of P-Glycoprotein in MDR1-Transduced Human Breast Cancer Cells. Cancer Science, 97, 1198-1204.
https://doi.org/10.1111/j.1349-7006.2006.00300.x
|
[22]
|
郑小维, 陈思颖, 张蔚鹏, 等. 乳腺癌多药耐药机制及其逆转策略研究进展[J]. 中国药房, 2015, 26(20): 135-138.
|
[23]
|
谢亚琳, 梁继珍, 苏宁. 吉非替尼与厄洛替尼在EGFR基因敏感突变晚期NSCLC患者一线治疗中的疗效比较[J]. 南方医科大学学报, 2015, 35(3): 446-449.
|
[24]
|
夏雯, 王树森. 激素受体阳性乳腺癌靶向治疗进展[J]. 中国肿瘤临床, 2017,44(13): 635-639.
|
[25]
|
张圣村, 马敏, 徐丽丽. 阿帕替尼逆转P-gp转运体介导的乳腺癌化疗多药耐药性的作用及其机制[J]. 肿瘤防治研究, 2018, 45(4): 210-214.
|
[26]
|
Zhang, X., Zhang, B., Liu, J., et al. (2015) Mechanisms of Gefitinib-Mediated Reversal of Tamoxifen Resistance in MCF-7 Breast Cancer Cells by Inducing ERα Re-Expression. Scientific Reports, 5, Article No. 7835.
https://doi.org/10.1038/srep07835
|
[27]
|
Gee, J.M.W., Harper, M., Hurcheson, I., et al. (2003) The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro. Endocrinology, 144, 5105-5017. https://doi.org/10.1210/en.2003-0705
|
[28]
|
赖艳, 温悦, 卢来春. 胡椒碱对乳腺癌阿霉素耐药细胞株MCF-7/ADM细胞的逆转作用[J]. 中国药业, 2014, 23(15): 23-24.
|
[29]
|
Yuan, W.Q., Zhang, R.R., Wang, J., et al. (2016) Asclepiasterol, a Novel C21 Steroidal Glycoside Derived from Asclepias curassavica, Reverses Tumor Multidrug Resistance by Down-Regulating P-Glycoprotein Expression. Oncotarget, 7, 31466-31483. https://doi.org/10.18632/oncotarget.8965
|
[30]
|
孙凯, 孙菊萍. 雷公藤红素逆转乳腺癌细胞对多柔比星的耐药性及机制研究[J]. 浙江中西医结合杂志, 2017, 27(3): 184-188.
|
[31]
|
袁婷婷, 张乃丹, 何勇静, 等. 天然药物中植物雌激素样化学成分的研究进展[J]. 中国中药杂志, 2014, 39(23): 4526-4531.
|
[32]
|
Zhang, B., Zhang, X., Tang, B., et al. (2012) Investigation of Elemene-Induced Reversal of Tamoxifen Resistance in MCF-7 Cells through Oestrogen Receptor α (ERα) Re-Expression. Breast Cancer Research & Treatment, 136, 399-406. https://doi.org/10.1007/s10549-012-2263-6
|
[33]
|
程曼, 何坤, 李晶, 等. 铁螯合剂通过抑制P-gp的表达促进乳腺癌化疗增敏[J]. 生物医学工程学进展, 2017, 38(3): 135-139.
|